Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St futures rise on Mideast deal optimism; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
RBC Capital on Acadia Pharmaceuticals (ACAD): 'We see a -1-2% stock move off the Nuplazid slight miss for 1Q23'
May 8, 2023 4:39 PM EDTRBC Capital analyst Gregory Renza reiterated an Outperform rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "Potential stock impact & bottom line: We see a -1-2% stock move off the Nuplazid slight miss for 1Q23, reiterated FY23 revenue guidance, offset by optimism around Daybue launch... More
